Moderna Cancer Vaccine Trial, 42% Recurrence Drop & Key Reality Check
Merck and Moderna have tested an experimental personalised mRNA cancer vaccine, intismeran, on melanoma patients following tumour resection surgery. Administered alongside the immunotherapy drug Keytruda, the combination regimen cut the risk of cancer recurrence or death by 42 percent after two years, with 82 percent remaining recurrence-free compared to 70 percent on Keytruda alone. Marking…